ObjectiveThis conference will offer an overview of EU legislation and the most relevant case law of the Court of Justice of the EU on transparency and patient access to information on medicinal products. Since the review of EU pharmaceutical legislation which entered into force in 2005 measures to promote such access have constantly increased.Key topicsLegal and practical implications of the proposal for a Regulation amending Regulation (EC) No 726/2004 as regards information to the general public on medicinal products for human use subject to medical prescription (COM (2012) 48 and 49)Access to documents versus protection of confidential information: marketing authorisation application dossiers, access to Eudrapharm as provided for in the Proposal for a Regulation on clinical trials on medicinal products for human use (COM (2012) 369)Transparency in national decisions on pricing and reimbursementState of play of the proposal for a new Directive relating to the transparency of measures regulating the pricing of medicinal products for human use (COM (2012) 84),Strengthening of national rules regarding transparency in the relations between pharmaceutical companies and healthcare professionals